White Paper

Streamlining The Upstream Workflow For Plasmid DNA Manufacturing

By Kayla J. Spivey, Thermo Fisher Scientific

Thermo Fisher

With the demand created by mRNA vaccines and compounded by the emerging cell and gene therapy market, the need for large-scale production of GMP-grade materials for biological products has never been greater.

Finding a way to increase manufacturing capacity while maintaining high-quality standards poses a unique challenge. The demand for reproducible, high-quality, and customizable bioprocessing material is forecasting its continued growth through 2025.

Culture medium and fermentation protocols are pivotal in maintaining a high-quality optimal percent yield while minimizing contaminants that will need to be removed during purification and downstream process steps. Here we will discuss the scalable process workflow solutions available from initial R&D investment to clinical testing, and commercialization.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online